Transferable Exclusivity Extension Vouchers Are Viable In Europe, But Back Up Required
Executive Summary
A new study shows that transferable exclusivity extension vouchers are the best way of incentivizing antibiotic development in Europe. However, investors caution that other strategies must also be considered.
You may also be interested in...
WHO Tightens Up Guidance On Reserving Most Critical Antimicrobials For Humans Only
All new classes of antimicrobials for human use will fall within the World Health Organization’s highest criticality category under its latest guidance on preventing antimicrobial resistance.
EU’s AMR Transferable Exclusivity Voucher Plan 'Not Fit For Purpose'
A European public health NGO has disputed the suggestion that a transferable exclusivity extension is the answer to the lack of innovative antimicrobial drugs in company pipelines.
England: Shionogi And Pfizer Ink ‘World First’ Payment Model Deal For Antibiotics
Shionogi and Pfizer have formally agreed to a scheme that offers companies a new and sustainable payment model for innovating in antibiotics.